Mosunetuzumab Biosimilar – Research Grade [ICH5026]

ichorbio’s mosunetuzumab biosimilar is for Research Use Only (RUO) and not for therapeutic use.

ichorbio’s RUO mosunetuzumab biosimilar is available in the following sizes:
1mg, 5mg, 10mg, 20mg
ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar – please contact us for pricing.

CD3e/CD20

Bispecific

BTCT4465A

CHO cells

Human

Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as mosunetuzumab.

This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

ichorbio’s Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells..

1.0 – 5.0 mg/ml

Sterile, preservative-free, solution in PBS. BSA and Azide free.

>95% by SDS-PAGE and HPLC

≤ 1.0 EU/mg as determined by the LAL method

Mosunetuzumab biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Functional Assays

Each investigator should determine their own optimal working dilution for specific applications.